ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
118.532,68
-1,33%
S&P 500
5.942,47
1,26%
US Dollar vs BRL
6,1822
0,00%
Bitcoin
98.037,81
-0,17%
Brent Oil
76,495
0,00%
As Melhores Corretoras Online
Registration Strip Icon for pro Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NYSE
  6. Organon and Co (OGN)

  7. Organon and Co (OGN) Notícias

OGN

Organon (OGN)

Organon and Co
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NYSE:OGN
DataHoraFonteTítuloCódigoCompanhia
23/12/202408:01Edgar (US Regulatory)Form 8-K - Current reportNYSE:OGNOrganon and Co
19/12/202409:30Business WireOrganon To Present at the 43rd Annual J.P. Morgan Healthcare ConferenceNYSE:OGNOrganon and Co
16/12/202409:30Business WireFDA Approves VTAMA® (tapinarof) cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and OlderNYSE:OGNOrganon and Co
05/11/202409:29Business WireUpdate on FDA Review of VTAMA® (tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and OlderNYSE:OGNOrganon and Co
01/11/202409:06Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NYSE:OGNOrganon and Co
31/10/202409:40Business Wire米国FDAが、PROLIA/XGEVA（デノスマブ）のバイオシミラー候補HLX14の生物学的製剤承認申請（BLA）を受理NYSE:OGNOrganon and Co
31/10/202409:39Business WireUS-amerikanische FDA akzeptiert BLA für HLX14 – den Biosimilar-Kandidat zu PROLIA/XGEVA (Denosumab)NYSE:OGNOrganon and Co
31/10/202409:39Business Wire美國FDA接受PROLIA/XGEVA（地諾單抗）生物學名藥候選藥物HLX14的生物製品授權申請(BLA)NYSE:OGNOrganon and Co
31/10/202408:30Business WireOrganon Reports Results for the Third Quarter Ended September 30, 2024NYSE:OGNOrganon and Co
31/10/202401:02Business WireLa FDA des États-Unis accepte la demande de licence de produits biologiques (BLA) pour HLX14, le candidat biosimilaire de PROLIA/XGEVA (denosumab)NYSE:OGNOrganon and Co
30/10/202407:00Business WireUS FDA Accepts Biologics License Application (BLA) for HLX14, Biosimilar Candidate of PROLIA/XGEVA (denosumab)NYSE:OGNOrganon and Co
29/10/202413:22Business WireOrganon vollzieht Übernahme von Dermavant einschließlich der innovativen dermatologischen Therapie VTAMA® (Tapinarof) Creme, 1 %NYSE:OGNOrganon and Co
29/10/202413:22Business Wireオルガノン、ダーマバントの買収を完了し、画期的な皮膚科治療薬VTAMA®（タピナロフ）クリーム1％を取得NYSE:OGNOrganon and Co
29/10/202413:22Business WireOrganon conclut l'acquisition de Dermavant, qui propose notamment un traitement dermatologique innovant : la crème VTAMA® (tapinarof) 1 %NYSE:OGNOrganon and Co
28/10/202410:25Business WireOrganon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%NYSE:OGNOrganon and Co
09/10/202408:30Business WireOrganon to Report Third Quarter 2024 Results and Host Conference Call on October 31, 2024NYSE:OGNOrganon and Co
08/10/202409:01PR Newswire (Canada)Organon Canada Promotes Geneviève Gauthier as Executive Director, Corporate Affairs and Community Engagement and Appoints Jeffrey Malawski as Executive Director, Women's Health and Established BrandsNYSE:OGNOrganon and Co
08/10/202409:01PR Newswire (Canada)Organon Canada promeut Geneviève Gauthier au poste de directrice exécutive, Affaires corporatives et Engagement communautaire, et nomme Jeffrey Malawski comme directeur exécutif, Santé des femmes et marques établiesNYSE:OGNOrganon and Co
30/09/202416:26Business Wireパージェタ（Perjeta®）（ペルツズマブ）バイオシミラー候補HLX11の第3相比較臨床試験で主要評価項目を達成NYSE:OGNOrganon and Co
30/09/202413:17Business WirePrimärer Endpunkt in Phase-3-Vergleichsstudie zu Perjeta® (Pertuzumab) Biosimilar-Kandidat HLX11 erreichtNYSE:OGNOrganon and Co
30/09/202412:59Business WireCritères principal atteint dans une étude clinique comparative de phase 3 sur le candidat biosimilaire HLX11 du Perjeta® (pertuzumab)NYSE:OGNOrganon and Co
30/09/202407:00Business WirePrimary Endpoint Met in Phase 3 Comparative Clinical Study of Perjeta® (pertuzumab) Biosimilar Candidate HLX11NYSE:OGNOrganon and Co
26/09/202410:50PR Newswire (Canada)Organon Canada and the Alberta Women's Health Foundation unite to raise awareness and advocate for universal access to contraception in CanadaNYSE:OGNOrganon and Co
26/09/202410:49PR Newswire (Canada)Organon Canada et l'Alberta Women's Health Foundation s'unissent pour accroître la sensibilisation et prôner l'accès universel à la contraception au CanadaNYSE:OGNOrganon and Co
19/09/202415:30Business WireオルガノンがDermavantを買収し、画期的な皮膚科治療薬VTAMA®（タピナロフ）クリーム1%を取得NYSE:OGNOrganon and Co
19/09/202409:00Business WireOrganon acquiert Dermavant et sa thérapie dermatologique innovante, la crème VTAMA® (tapinarof), 1 %NYSE:OGNOrganon and Co
19/09/202409:00Business WireOrganon erwirbt Dermavant und dessen innovative dermatologische Behandlung VTAMA® (Tapinarof) Creme, 1 %NYSE:OGNOrganon and Co
18/09/202408:30GlobeNewswire Inc.Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%NYSE:OGNOrganon and Co
05/09/202417:32Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:OGNOrganon and Co
20/08/202421:13Business Wireオルガノンとリリーが片頭痛治療薬の商業化契約を拡大、11の新しい市場に参入NYSE:OGNOrganon and Co
 Apresentando as notícias mais relevantes sobre:NYSE:OGN

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
PRIO3
PETRORIO ON
BOV
AZEV4
AZEVEDO PN
BOV
PCAR3
PÃO DE AÇUCAR ON
BOV
USIM5
USIMINAS PNA
BOV
FICT3
Fictor Alimentos ON
BOV
AMER3
Americanas ON
BOV
MGLU3
MAGAZINE LUIZA ON
BOV
COGN3
COGNA ON
BOV
SEQL3
Sequoia Logistica e Tran... ON
BOV
INBR32
Inter &
BOV
IDIV
Dividend
BOV
RAIZ4
Raizen S.A PN
BOV
BRSR6
BANRISUL PNB
BOV
AMBP3
Ambipar Participacoes e ... ON
BOV
GFSA3
GAFISA ON
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2025 ADVFN PLC - Todos os direitos reservados